Eli Lilly And Co (NYSE:LLY) and Amgen, Inc. (NASDAQ:AMGN) have announced a new partnership that will facilitate higher production of antibody-based treatments for the coronavirus.
News of the partnership between the two companies came barely two days after Eli Lilly pipeline antibody proved effective in helping patients to clear the coronavirus infection from their body in 11 days. The treatment therefore has the potential to reduce hospitalization while also providing a leg-up against the pandemic. Amgen will help Eli Lilly to boost the production capacity for the antibody treatment.
“We are impressed with Lilly’s data, in particular the reduction in hospitalizations, and are enthusiastic about the potential for these neutralizing antibodies as a therapeutic for Covid-19,” stated Amgen’s head of research and development, David Reese.
Is Eli Lilly preparing to roll out the treatment?
The recent announcement regarding the antibody treatment’s ability to combat the coronavirus vaccine was from interim data. However, Eli Lilly is highly optimistic that the final results will be favorable. The company also revealed that it plans to submit the interim data to the FDA and other global regulators or the possibility of emergency use approval.
The announcement regarding the production partnership means that the company might just be ensuring that it has the right measures in place in case it receives approval for mass rollout. However, it could also mean that the company is confident enough that it is pushing forward with early preparations for the antibody treatment’s mass production. If this is the case, then there is a chance that the treatment might be available within a few months.
Antibody therapies are often quite promising because they are based on the natural immune system. When a person gets sick, the body synthesizes antibodies that help to combat the infection. Eli Lilly collected antibodies from individuals that had previously contracted the coronavirus and survived. Biopharmas study the antibodies collected from the plasma of recovered patients and they use the information to create synthetic versions of the antibodies. This approach can be highly effective in rapidly developing treatments for viral illnesses.